查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球無內胎胰島素幫浦市場 - 2023-2030
市場調查報告書
商品編碼
1374847

全球無內胎胰島素幫浦市場 - 2023-2030

Global Tubeless Insulin Pumps Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 187 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

無管胰島素幫浦基本上是作為貼片直接佩戴在身體上，並透過無線手持設備進行控制，從而實現謹慎的胰島素輸送。此幫浦沒有螢幕，由觸控螢幕手持裝置透過藍牙進行無線控制。它包括放置在防水閉迴路胰島素幫浦中的演算法，並直接與連續血糖監測儀通訊以實現胰島素釋放過程。

此外，無管胰島素幫浦可以幫助第1型和第2型糖尿病患者方便地管理血糖值。這些小型設備在特定時間內提供一定劑量的胰島素。無管胰島素幫浦是比胰島素筆注射和其他胰島素設備更靈活的選擇。這些不一定是永久性的，可以隨時切換到另一種胰島素管理方法。無管胰島素幫浦對患者有利，可以使用無線設備進行胰島素輸送。

市場動態：促進因素

無管胰島素幫浦不斷進步

無內胎幫浦的不斷進步預計將在預測期內推動市場發展。這些幫浦的進步預計將增加無管胰島素幫浦的採用。無管胰島素幫浦技術的進步可能會導致設備更小、更舒適、更容易使用。使用者體驗的改善可以提高患者滿意度。

例如，2023年8月，羅氏推出了Accu-Chek Solo胰島素貼片幫浦和無線觸控螢幕手持設備，並已獲得FDA核准用於2歲及以上糖尿病患者。該系統包括一個無管胰島素幫浦和一個帶藍牙的無線手持控制器，該控制器整合了血糖監測並提供推注建議。此胰島素幫浦系統無管、體積小、重量輕。該裝置是可拆卸的，允許糖尿病患者在必要時改變輸注部位。

此外，如果無管胰島素幫浦設計為與 CGM 系統無縫整合，從而實現更好的血糖監測和自動胰島素調整，則可以顯著增強糖尿病管理。這會帶來更好的患者治療結果，並進一步增加先進設備的採用。

例如，2023 年 6 月 20 日，全球無管胰島素幫浦技術領導者 Insulet Corporation 及其 Omnipod 品牌產品推出了 Omnipod 5 自動胰島素輸送系統 (Omnipod 5)，適用於 2 歲及以上 1 型糖尿病患者在英國。 Omnipod 5 系統是簡單性與先進技術的結合。 Omnipod 5 是首款獲得 CE 標誌的無內胎混合閉迴路系統，與 Dexcom G6 連續血糖監測 (CGM) 系統整合，可自動調節胰島素輸送並幫助防止血糖水平過高或過低。

此外，無線連接和無管胰島素幫浦智慧功能的結合可以讓使用者透過數位平台監控和控制胰島素輸送。這種程度的連接可以提高患者的便利性。總體而言，無管胰島素幫浦的進步提高了使用者的便利性並進一步提高了採用率。

例如，2023 年 2 月 14 日，EOFlow Co. 在阿拉伯聯合大公國推出了無內胎、穿戴式、拋棄式胰島素幫浦 EOPatch。在阿拉伯聯合大公國，可以使用全新的 Narsha 應用程式直接透過 Android 和 iOS 智慧型手機透過 EOPatch 控制和管理胰島素輸注。

此外，糖尿病盛行率的增加、FDA 批准等監管部門的批准不斷增加、人們對無管胰島素幫浦優勢的認知不斷提高以及設備的技術進步預計將在預測期內推動市場發展。

限制

無管胰島素幫浦相關的併發症和風險以及這些設備的高成本等因素預計將阻礙市場的發展。

目錄

第 1 章：方法與範圍

  • 研究方法論
  • 報告的研究目的和範圍

第 2 章：定義與概述

第 3 章：執行摘要

  • 按類型分類
  • 按組件分類
  • 按應用程式片段
  • 按配銷通路分類
  • 按地區分類

第 4 章：動力學

  • 影響因素
    • 促進要素
      • 無內胎胰島素幫浦不斷進步
    • 限制
      • 設備成本高
    • 機會
    • 影響分析

第 5 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • 管道分析
  • 未滿足的需求
  • DMI 意見

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆發前的情景
    • 新冠疫情期間的情景
    • 新冠疫情後的情景
  • COVID-19 期間的定價動態
  • 供需譜
  • 疫情期間政府與市場相關的舉措
  • 製造商策略舉措
  • 結論

第 7 章：按類型

  • 胰島素貼片泵
  • 附拋棄式儲液器的傳統泵

第 8 章：按組件

  • 胰島素幫浦（莢）
  • 遙控器

第 9 章：按應用

  • 1 型糖尿病
  • 2型糖尿病

第 10 章：按配銷通路

  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 11 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 亞太其他地區
  • 中東和非洲

第 12 章：競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 13 章：公司簡介

  • Insulet Corporation
    • 公司簡介
    • 產品組合和描述
    • 財務概覽
    • 主要進展
  • F. Hoffmann-La Roche Ltd
  • Debiotech SA
  • CeQur Corporation
  • Terumo Corporation
  • Tandem Diabetes Care, Inc.
  • EOFLOW CO., LTD.
  • Medtrum Technologies Inc.
  • Microtec Medical
  • Ascensia Diabetes Care Holdings AG

第 14 章：附錄

簡介目錄
Product Code: MD7390

Overview

Tubeless insulin pumps are basically worn as a patch directly on the body and controlled from a wireless handheld device, enabling discreet insulin delivery. The pump does not have a screen and is controlled wirelessly from a touchscreen handheld via Bluetooth. It includes an algorithm placed in a waterproof, closed-loop insulin pump and communicates directly with a continuous glucose monitor for the insulin-releasing process.

Moreover, tubeless insulin pumps can help people with type-1 and type-2 diabetes conveniently to manage their blood sugar levels. These small devices deliver doses of insulin at specific times. The tubeless insulin pumps are a more flexible option than insulin pen injections and other insulin devices. These don't have to be permanent and can switch to another insulin management method at any time. Tubeless insulin pumps are favorable to the patients, insulin delivery can be done by using wireless devices.

Market Dynamics: Drivers

Increasing advancements in tubeless insulin pumps

The increasing advancements in tubeless pumps are expected to drive the market over the forecast period. The advancements in these pumps are expected to increase the adoption of tubeless insulin pumps. Advancements in tubeless insulin pump technology may result in devices that are smaller, more comfortable, and easier to use. Improvements in user experience can lead to increased patient satisfaction.

For instance, in August 2023, Roche launched its Accu-Chek Solo insulin patch pump and wireless touchscreen handheld device and it has received FDA approval for people with diabetes aged 2 years and older. The system includes a tubeless insulin pump and a wireless handheld controller with Bluetooth, which integrates with blood glucose monitoring and provides bolus advice. This insulin pump system is tubeless, small and lightweight. The device is detachable, allowing people with diabetes to change the infusion site when necessary.

Moreover, if tubeless insulin pumps are designed to integrate seamlessly with CGM systems, allowing for better glucose monitoring and automated insulin adjustments, it can significantly enhance diabetes management. This results in better patient outcomes and further this increases the adoption of advanced devices.

For instance, on June 20, 2023, Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod brand of products, launched its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes in the United Kingdom. The Omnipod 5 System is where simplicity meets advanced technology. Omnipod 5 is the first CE-marked tubeless hybrid closed loop system that integrates with the Dexcom G6 Continuous Glucose Monitoring (CGM) System to automatically adjust insulin delivery and help protect against high and low glucose levels.

Furthermore, the incorporation of wireless connectivity and smart features of tubeless insulin pumps can empower users to monitor and control their insulin delivery through digital platforms. This level of connectivity can improve patient convenience. Overall, the advancements in tubeless insulin pumps improve user convenience and further increase adoption.

For instance, on February 14, 2023, EOFlow Co. launched its tubeless, wearable, and disposable insulin pump EOPatch in the UAE. It becomes possible in the UAE to control and manage insulin infusions with EOPatch directly from Android and iOS smartphones using the brand-new Narsha app.

In addition, the increasing prevalence of diabetes, rising regulatory approvals such as FDA approvals, increasing awareness about the advantages of tubeless insulin pumps and technological advancements in the devices are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications and risks associated with tubeless insulin pumps and the high cost of these devices are expected to hamper the market.

Segment Analysis

The global tubeless insulin pumps market is segmented based on type, component, application, distribution channel and region.

The insulin patch pumps segment accounted for approximately 43.2% of the tubeless insulin pumps market share

The insulin patch pumps segment is expected to hold the largest market share over the forecast period. Insulin patch pumps are a type of wearable insulin delivery device that adheres to the skin, typically in the form of a patch. These pumps are designed to provide a continuous delivery of insulin. They offer advantages such as discreetness, ease of use, and reduced interference with daily activities.

Moreover, insulin patch pumps are usually designed to adhere securely to the skin, allowing users to wear them for an extended period without discomfort. For instance, on November 16, 2022, Dexcom U.K. launched a campaign led by four local celebrities who designed their own continuous glucose monitor (CGM) insulin patch pumps to tell their Diabetes Story.

Due to the rising prevalence of diabetes, there is a continuously increasing demand for the use of tubeless insulin pumps. For instance, according to the Centers for Disease Control and Prevention, 2022, there are a total of 37.3 million people have diabetes. These insulin patch pumps are often compact and discreet, making them less noticeable and more convenient for users.

Geographical Analysis

North America accounted for approximately 39.2% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing advancements. North America especially the United States is home to the presence of major players such as medical device companies, which are primarily focussing on the development of tubeless insulin pumps by offering more advanced features to increase patient convenience.

For instance, on April 25, 2023, Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod brand of products, released the FDA clearance of its latest innovation, Omnipod GO, an insulin delivery device cleared for use for people with type 2 diabetes age 18 or older who would typically take daily injections of long-acting insulin. With its tubeless and waterproof pod, the Omnipod GO provides an alternative to traditional insulin delivery methods.

Furthermore, increasing advancements for tubeless insulin pumps in the region are also expected to drive the market in the region. For instance, on August 11, 2022, EOFlow officially launched its tubeless, wearable, and disposable insulin pump under the diabetes care brand GlucoMen Day PUMP. These advancements increase the adoption of tubeless insulin pumps in the region.

Competitive Landscape

The major global players in the tubeless insulin pumps market include: Insulet Corporation, F. Hoffmann-La Roche Ltd, Debiotech SA, CeQur Corporation, Terumo Corporation, Tandem Diabetes Care, Inc., EOFLOW CO., LTD., Medtrum Technologies Inc., Microtec Medical and Ascensia Diabetes Care Holdings AG among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global tubeless insulin pumps market. During the pandemic, the demand for the tubeless insulin pumps has increased. For instance, according to NIH 2020, obesity and diabetes are two major risk factors for COVID-19 hospitalization. The organization stated that people with diabetes mellitus and severe obesity are more likely to get infected and are at a higher risk of mortality from COVID-19. Among elderly patients who are at higher risk of death from COVID-19, 26.8% have diabetes mellitus, this increased the demand for the adoption of tubeless insulin pumps. However, the pandemic also disrupted the supply chain of these devices globally.

Market Segmentation

By Type

  • Insulin Patch Pumps
  • Traditional Pumps with Disposable Reservoirs

By Component

  • Insulin Pump (Pod)
  • Remote Controller

By Application

  • Type-1 Diabetes
  • Type-2 Diabetes

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Why Purchase the Report?

  • To visualize the global tubeless insulin pumps market segmentation based on type, component, application, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of tubeless insulin pumps market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global tubeless insulin pumps market report would provide approximately 69 tables, 64 figures, and 187 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Component
  • 3.3. Snippet by Application
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Advancements in Tubeless Insulin Pumps
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of the Devices
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Unmet Needs
  • 5.7. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Insulin Patch Pumps*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Traditional Pumps with Disposable Reservoirs

8. By Component

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 8.1.2. Market Attractiveness Index, By Component
  • 8.2. Insulin Pump (Pod)*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Remote Controller

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Type-1 Diabetes*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Type-2 Diabetes

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Insulet Corporation*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. F. Hoffmann-La Roche Ltd
  • 13.3. Debiotech SA
  • 13.4. CeQur Corporation
  • 13.5. Terumo Corporation
  • 13.6. Tandem Diabetes Care, Inc.
  • 13.7. EOFLOW CO., LTD.
  • 13.8. Medtrum Technologies Inc.
  • 13.9. Microtec Medical
  • 13.10. Ascensia Diabetes Care Holdings AG

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us